Immunotech Biopharm Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 6978?
Owner Type	Number of Shares	Ownership Percentage
Institutions	323,066	0.0628%
State or Government	32,998,619	6.41%
Private Companies	51,458,400	10%
Public Companies	97,102,571	18.9%
General Public	105,412,058	20.5%
Individual Insiders	227,289,286	44.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 14 shareholders own 79.52% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
19.1%	Zheng Tan	98,194,286	HK$225.8m	0%	no data
18.9%	Tasly Pharmaceutical Group Co., Ltd	97,102,571	HK$223.3m	0%	no data
10%	China Resources Company Limited	51,458,400	HK$118.4m	0%	no data
8.71%	Hyun Chul Jung	44,820,000	HK$103.1m	0%	no data
8.1%	Junzheng Zhang	41,691,428	HK$95.9m	0%	no data
6.41%	Greater Bay Area Development Fund	32,998,619	HK$75.9m	0%	no data
2.67%	Shuhui Wang	13,714,286	HK$31.5m	0%	no data
2.03%	Xiaoou Ma	10,422,857	HK$24.0m	0%	no data
1.33%	Yuning Wang	6,857,143	HK$15.8m	0%	no data
1.07%	Shaobin Ke	5,485,714	HK$12.6m	0%	no data
0.8%	Aiping Song	4,114,286	HK$9.5m	0%	no data
0.39%	MinHui Wang	1,989,286	HK$4.6m	0%	no data
0.063%	China Universal Asset Management Company Ltd.	322,000	HK$740.5k	0%	no data
0.00021%	BMO Asset Management Corp.	1,066	HK$2.5k	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/02 11:47
End of Day Share Price	2025/01/02 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Immunotech Biopharm Ltd is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Lok Kwan Chiu	CCB International Securities Limited
Yidong Zhang	Industrial Securities (HK) Financial Holdings
Qianlan Zhu	SPDB International Holdings Limited